A 6 Day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of Gatifloxacin 0.5% Ophthalmic Solution BID with that of Vehicle in the Treatment of Acute Bacterial Conjunctivitis

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/08 → 12/31/08

Funding

  • Allergan Pharmaceuticals Inc: $3,916.00